X-VIVOTM 20 Serum-free Hematopoietic Cell Medium
X-VIVOTM 20 Serum-free Hematopoietic Cell Medium
X-VIVOTM 20, with L-Glutamine, gentamicin and phenol red, xenofree,1 L
Want to request a quote or find our more information about this product including customization options? Please fill in your request and your local sales specialist will contact you.
Select Size
Product Overview
X-VIVOTM 20 Medium is optimized to support the generation of lymphokine activated killer (LAK) cells from monocytedepleted peripheral blood lymphocytes (PBL) at high density. Initial cell densities between 2.0 – 3.0 × 107 cells/ ml can be used to successfully generate LAK cells. X-VIVOTM 20 Medium may also be used as a growth medium for PBL and tumor infiltrating lymphocytes (TIL).
All BioWhittakerTM Cell Culture Media products are for Research Use Only (RUO) and are not approved for human or veterinary use or for use in clinical or in vitro diagnostic procedures. If you require GMP grade media, contact Lonza for more details.
Request More InfoApplications
– Proliferation of peripheral blood lymphocytes
– Proliferation of tumor infiltrating lymphocytes
– Cryopreservation of human tissue
– Cultivation of human monocytes and macrophages
– Cultivation of stem cells – Cultivation of dendritic cells
Storage and Content
- 1L bottle
SDS, CoA, and Instructions
Safety Data Sheets (SDS)
Choose a language to view the SDS.
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
Educational Material
Brochures, White Papers etc.
-
Developing Patient-specific Cell Therapy Manufacturing Processes
Poster presentation about patient-specific cellular therapies and their tremendous potential for being able to treat life threatening diseases where there are currently no cures. -
CAR T cells in Cancer Therapy
A poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.